Novartis
NEWS
Novartis, a leader reimagining rheumatology and immunodermatology, announced positive new data from the PREVENT trial evaluating the efficacy and safety of Cosentyx® (secukinumab) in patients with nr-axSpA (non-radiographic axial spondyloarthritis).
The trial is still ongoing, but met its primary endpoint of ASAS40.
Last week was a busy one for clinical trial results, particularly with the European Committee for Treatment and Research in Multiple Sclerosis 2019 Congress going on. Here’s a look at some of the top clinical trial stories.
Novartis Chief Executive Officer Vas Narasimhan has pledged the company will be more forthcoming with the U.S. Food and Drug Administration and other regulatory agencies regarding data mismanagement and manipulations in the future.
Last week was a busy week for clinical trial results. Here’s a look at some of the top stories and reporting.
The companies will develop a group of immunotherapies that inhibit the cGAS/STING pathway to treat a broad range of inflammatory and autoimmune diseases.
The trials were the PROVE-HF and EVALUATE-HF trials.
Rounding out the traditional summer months, last week had plenty of clinical trial news. Here’s a look at some of the top stories.
The trials met the primary endpoints, with ofatumumab demonstrating a highly significant and clinically meaningful decrease in the number of confirmed relapses. The trials also hit key secondary endpoints, delaying the time to confirmed disability progression.
JOBS
IN THE PRESS